Ezatiostat hydrochloride for the treatment of myelodysplastic syndromes

Bibliography

• Sabattini E, Bacci F, Sagramoso C, et al. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica 2010;102(3):83-7
   PubMedGoogle Scholar
• Radlund A, Thiede T, Hansen S, et al. Incidence of myelodysplastic syndromes in a Swedish population. Eur J Haematol 1995;54(3):153-6
   PubMed Web of Science ®Google Scholar
• Dinmohamed AG, Visser O, van Norden Y, et al. Trends in incidence, initial treatment and survival of myelodysplastic syndromes: a population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010. Eur J Cancer 2014;50(5):1004-12
   PubMed Web of Science ®Google Scholar
• McQuilten ZK, Wood EM, Polizzotto MN, et al. Underestimation of myelodysplastic syndrome incidence by cancer registries: results from a population-based data linkage study. Cancer 2014;120(11):1686-94
   PubMed Web of Science ®Google Scholar
• Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89(6):2079-88
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012;120(12):2454-65
   PubMed Web of Science ®Google Scholar
• Savic A, Marisavljevic D, Kvrgic V, et al. Validation of the Revised International Prognostic Scoring System for patients with myelodysplastic syndromes. Acta Haematol 2014;131(4):231-8
   PubMed Web of Science ®Google Scholar
• Tothova Z, Steensma DP, Ebert BL. New strategies in myelodysplastic syndromes: application of molecular diagnostics to clinical practice. Clin Cancer Res 2013;19(7):1637-43
   PubMed Web of Science ®Google Scholar
• Schanz J, Tuchler H, Sole F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 2012;30(8):820-9
   PubMed Web of Science ®Google Scholar
• Malcovati L, Hellstrom-Lindberg E, Bowen D, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 2013;122(17):2943-64
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Sun Z, Miller KB, et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood 2009;114(12):2393-400
   PubMed Web of Science ®Google Scholar
• Sierra J, Perez WS, Rozman C, et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 2002;100(6):1997-2004
   PubMed Web of Science ®Google Scholar
• de Witte T, Hagemeijer A, Suciu S, et al. Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial. Haematologica 2010;95(10):1754-61
   PubMed Web of Science ®Google Scholar
• Miller KB, Kim K, Morrison FS, et al. The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study. Ann Hematol 1992;65(4):162-8
   PubMed Web of Science ®Google Scholar
• Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006;24(24):3895-903
   PubMed Web of Science ®Google Scholar
• List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005;352(6):549-57
   PubMed Web of Science ®Google Scholar
• Wei S, Chen X, Rocha K, et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci USA 2009;106(31):12974-9
   PubMed Web of Science ®Google Scholar
• Jonasova A, Bokorova R, Polak J, et al. High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide. Eur J Haematol 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Fink EC, Kronke J, Hurst S, et al. Lenalidomide induces ubiquitination and degradation of CSNK1A1 in MDS with Del(5q). Annual Meeting ASH ASH Annual Meeting; 7th December 2014
   Google Scholar
• Weiss AJ, Metter GE, Nealon TF, et al. Phase II study of 5-azacytidine in solid tumors. Cancer Treat Rep 1977;61(1):55-8
   PubMedGoogle Scholar
• Weiss AJ, Stambaugh JE, Mastrangelo MJ, et al. Phase I study of 5-azacytidine (NSC-102816). Cancer Chemother Rep 1972;56(3):413-19
   PubMedGoogle Scholar
• Jones PA, Taylor SM, Wilson VL. Inhibition of DNA methylation by 5-azacytidine. Recent Results Cancer Res 1983;84:202-11
   PubMedGoogle Scholar
• Taylor SM, Jones PA. Mechanism of action of eukaryotic DNA methyltransferase. Use of 5-azacytosine-containing DNA. J Mol Biol 1982;162(3):679-92
   PubMed Web of Science ®Google Scholar
• Hollenbach PW, Nguyen AN, Brady H, et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One 2010;5(2):e9001
   PubMed Web of Science ®Google Scholar
• Kimura S, Kuramoto K, Homan J, et al. Antiproliferative and antitumor effects of azacitidine against the human myelodysplastic syndrome cell line SKM-1. Anticancer Res 2012;32(3):795-8
   PubMed Web of Science ®Google Scholar
• Steensma DP, Baer MR, Slack JL, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 2009;27(23):3842-8
   PubMed Web of Science ®Google Scholar
• Pang WW, Pluvinage JV, Price EA, et al. Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes. Proc Natl Acad Sci USA 2013;110(8):3011-16
   PubMed Web of Science ®Google Scholar
• Xia Z, Dickens M, Raingeaud J, et al. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995;270(5240):1326-31
   PubMed Web of Science ®Google Scholar
• Adler V, Yin Z, Fuchs SY, et al. Regulation of JNK signaling by GSTp. EMBO J 1999;18(5):1321-34
   PubMed Web of Science ®Google Scholar
• Henderson CJ, Smith AG, Ure J, et al. Increased skin tumorigenesis in mice lacking pi class glutathione S-transferases. Proc Natl Acad Sci USA 1998;95(9):5275-80
   PubMed Web of Science ®Google Scholar
• Widersten M, Kolm RH, Bjornestedt R, et al. Contribution of five amino acid residues in the glutathione-binding site to the function of human glutathione transferase P1-1. Biochem J 1992;285(Pt 2):377-81
   PubMedGoogle Scholar
• Wang L, Groves MJ, Hepburn MD, et al. Glutathione S-transferase enzyme expression in hematopoietic cell lines implies a differential protective role for T1 and A1 isoenzymes in erythroid and for M1 in lymphoid lineages. Haematologica 2000;85(6):573-9
   PubMed Web of Science ®Google Scholar
• Ruscoe JE, Rosario LA, Wang T, et al. Pharmacologic or genetic manipulation of glutathione S-transferase P1-1 (GSTpi) influences cell proliferation pathways. J Pharmacol Exp Ther 2001;298(1):339-45
   PubMed Web of Science ®Google Scholar
• Raza A, Galili N, Callander N, et al. Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome. J Hematol Oncol 2009;2:20
   PubMedGoogle Scholar
• Raza A, Galili N, Mulford D, et al. Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS). J Hematol Oncol 2012;5:18
   PubMed Web of Science ®Google Scholar
• Raza A, Galili N, Smith S, et al. Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome. Blood 2009;113(26):6533-40
   PubMed Web of Science ®Google Scholar
• Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108(2):419-25
   PubMed Web of Science ®Google Scholar
• Raza A, Galili N, Smith SE, et al. A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome. Cancer 2012;118(8):2138-47
   PubMed Web of Science ®Google Scholar
• Galili N, Tamayo P, Botvinnik OB, et al. Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome. J Hematol Oncol 2012;5:20
   PubMed Web of Science ®Google Scholar
• Ma X. Epidemiology of myelodysplastic syndromes. Am J Med 2012;125(7 Suppl):S2-5
   PubMed Web of Science ®Google Scholar
• Bejar R, Steensma DP. Recent developments in myelodysplastic syndromes. Blood 2014;124(18):2793-803
   PubMed Web of Science ®Google Scholar
• Lyons RM, Wilks ST, Young S, et al. Oral ezatiostat HCl (Telintra(R), TLK199) and idiopathic chronic neutropenia (ICN): a case report of complete response of a patient with G-CSF resistant ICN following treatment with ezatiostat, a glutathione S-transferase P1-1 (GSTP1-1) inhibitor. J Hematol Oncol 2011;4:43
   PubMed Web of Science ®Google Scholar
• Prebet T, Sun Z, Figueroa ME, et al. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. J Clin Oncol 2014;32(12):1242-8
   PubMed Web of Science ®Google Scholar
• Carrancio S, Markovics J, Wong P, et al. An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin. Br J Haematol 2014;165(6):870-82
   PubMed Web of Science ®Google Scholar
• Yang H, Bueso-Ramos C, DiNardo C, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia 2014;28(6):1280-8
   PubMed Web of Science ®Google Scholar